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Abstract
Introduction In recent years, it has been realized that innate
lymphocytes do not act in isolation but potentiate their
efficiency by interacting with each other, resulting even in
the regulation of adaptive immune response. One such
cross-talk exists between dendritic cells (DCs) and natural
killer (NK) cells. Here, we summarize recent studies on
which subsets of these two innate immune components
participate in this interaction, how it influences immune
responses, and to which extent similar stimuli are integrated
by DCs and NK cells during innate immunity.
Conclusion We suggest that this cross-talk should be har-
nessed by activating both of these innate leucocyte popula-
tions with new adjuvant formulations for immunotherapies.
Keywords Myeloid dendritic cells . plasmacytoid dendritic
cells . natural killer cell subsets . interleukin-12 .
interleukin-15 . type I interferon . DC/NK cell cross-talk
Introduction
In the immune system, the different leukocytes act not only
by mediating their own protective functions, but also by
interacting with each other to optimize the response against
a pathogen. Recently, relevant liaisons, occurring between
natural killer (NK) cells and dendritic cells (DCs), have
been extensively investigated, and we will review NK cell
activation by DC, editing of DC induced immune responses
by NK cells, and an emerging similarity in target cell
recognition between these two innate leukocyte subsets.
Our discussion will primarily focus on human DC/NK cell
interactions.
DCs are critical for initiating immune responses [1]. At
an immature stage, they act as sentinels in peripheral
tissues, continuously sampling the environment, sensing the
presence of pathogens, and secreting chemokines and
cytokines to amplify the immune response. Upon activation
by danger signals, they up-regulate chemokine receptors
and costimulatory molecules, which allow them to migrate
into lymph nodes and to efficiently induce T-cell responses
[1].
NK cells were identified originally on a functional basis,
as this term was assigned to lymphoid cells capable of
killing a number of tumor cell lines in the absence of
previous stimulation in vivo and in vitro [2]. The molecular
mechanisms, by which NK cells discriminate between
normal and tumor cells were revealed in recent years. It
has been shown that NK cells recognize MHC class I
molecules through surface receptors delivering inhibitory
signals. As a consequence, NK cells can lyse target cells
that have lost (or express low amounts of) MHC class I
molecules, a frequent event in tumors or in cells infected by
certain cytopathic viruses, primarily herpes viruses. This
principle of NK cell activation was coined “missing-self”
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recognition [3]. Human NK cells express different HLA
class I-specific inhibitory receptors. Those named “killer
immunoglobulin (Ig)-like receptors” (KIR) are specific for
allelic determinants of HLA class I molecules. In contrast,
the Ig-like transcript (ILT)2 (LIR1) receptor is characterized
by a broad specificity for various HLA class I molecules,
while CD94/NKG2A recognizes the nonclassical MHC
class I molecule HLA-E [4–7].
In addition to detection of MHC class I loss, NK cells
require also an activating signal for target cell lysis.
Absence of activating ligands allows them to spare somatic
cells with low MHC class I expression like neurons, and
strong activating signaling leads to killing of MHC class I-
positive tumor cells. The archetypical activating NK cell
receptor is CD16 (FcγRIIIA) [8, 9]. This intermediate
affinity Fc receptor allows NK cells to target cells
opsonized with antibodies and to mediate antibody-
dependent cellular cytotoxicity (ADCC). Triggering recep-
tors specific for HLA class I molecules, displaying a high
homology with the corresponding inhibitory receptors, have
also been identified on subsets of NK cells [10–12].
However, these receptors cannot account for the NK cell-
mediated lysis of HLA class I negative target cells. Indeed,
the major receptors responsible for NK cell triggering in the
process of natural cytotoxicity are not HLA class I-specific.
Three receptors, termed NKp46, NKp30, and NKp44,
which are referred to collectively as “natural cytotoxicity
receptors” (NCR) were the first activating NK cell receptors
to be identified and characterized molecularly [5]. Although
a direct correlation has been established between the
surface density of NCR on NK cells and the intensity of
their cytolytic activity [13], only limited information is
available regarding the cell surface ligands recognized by
NCRs [14, 15]. An additional activating receptor, NKG2D,
is expressed not only by NK cells but also by cytotoxic T
lymphocytes. NKG2D recognizes the stress-inducible MIC-
A/B [16] and ULBPs proteins [17]. More recently, it has
been shown that DNAM-1, a triggering receptor expressed
by virtually all NK cells and partially shared with T
lymphocytes and monocytes, specifically recognizes PVR
(CD155) and Nectin-2 (CD112) [18], two members of the
nectin family. Other activating surface molecules include
2B4, NTBA, and NKp80 [5], which contribute to NK cell
triggering during the process of natural cytotoxicity.
However, it appears that they primarily play a role as
coreceptors, i.e., they may amplify the NK cell triggering
induced by NCR or NKG2D. Although activating NK cell
signals are, therefore, mediated by many receptors, all the
available data are compatible with the concept that the
ligands for NK cell-activating receptors are mainly
expressed by “stressed” cells (e.g., tumor and infected cells
or proliferating cells), for which genomic instability might
be one hallmark [19].
These NK cell receptors—both inhibitory and activating—
allowed for the subdivision of human NK cells and for the
analysis of the anatomical distribution of distinct NK cell
subsets, which resulted in new insights into NK cell
immunobiology.
NK Cell Subsets
For many years, NK cells were considered to be a
homogeneous lymphocyte population with excellent cyto-
toxic capability. Nowadays, NK cells rather appear to
comprise various subsets that differ in function, in
phenotype, and in anatomical localization.
In human peripheral blood (PB), the majority of NK
cells (≥95%) belongs to the CD56dimCD16 + cytolytic NK
subset [20–22]. These cells carry homing markers for
inflamed peripheral sites and perforin to rapidly mediate
cytotoxicity. The minor NK cell subset in blood (≤5%) is
CD56brightCD16− [20–22]. These NK cells lack perforin (or
display low level of it) but secrete large amounts of interferon
(IFN)-γ and tumor necrosis factor (TNF)-α upon activation
and are superior to CD56dim CD16 + NK cells in this latter
function [21, 22]. CD56brightCD16− NK cells proliferate
more vigorously than their CD56dimCD16 + counterparts.
Consistent with this feature, they uniquely express the high-
affinity receptor for interleukin (IL)-2 (CD25), the alpha
chain of IL-7 receptor and CD117, the receptor for the stem
cell factor, also named c-kit. In addition, they display
homing markers for secondary lymphoid organs, namely,
CCR7 and CD62L [20]. Notably, the major histocompatibil-
ity complex (MHC) class I allele-specific KIRs are expressed
on subsets of CD56dimCD16 + cytolytic NK cells, whereas
the immunoregulatory CD56brightCD16− NK subset
expresses uniformly CD94/NKG2A and lacks KIRs [21].
Therefore, two main functional NK cell subsets have been
characterized in peripheral blood, and we will discuss their
anatomical distribution next.
NK Cells in Inflamed and Malignant Tissues
During inflammation, activated myeloid DCs (mDCs) and
plasmacytoid DCs (pDCs) can secrete different chemokines
such as MIP-1β/CCL4, RANTES/CCL5, fractalkine/
CX3CL1, IL-8/CXCL8, and IP-10/CXCL10 [23–25]. The
different NK cell subsets are able to migrate in response to
these chemokines, according to the receptors they express.
CD56lowCD16 + NK cells express CXCR1 and CX3CR1
[20, 26], receptors for IL-8/CXCL8 and fractalkine/
CX3CL1, respectively. This last chemokine would mediate
the firm adhesion of cells to the endothelium and
subsequent migration toward IL-8 [27]. The CD56bright
NK cells express CCR5, CXCR3, and CXCR4 which allow
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them to migrate in response to RANTES/CCL5, MIP-1β/
CCL4, ITAC/CXCL11, and IP-10/CXCL10 [20]. Thus,
DCs would attract the two types of NK cells in the site of
inflammation, rendering their encounter possible. This
hypothetical interaction is supported by in vivo observations,
where NK cells have been found in close contact with DCs
either in lesions of atopic eczema/dermatitis syndrome or in
Gleevec-induced lichenoid dermatitis in gastrointestinal stro-
mal tumor (GIST) bearing patients [28, 29]. However, in
autoimmune inflamed lesions primarily the CD56brightCD16−
NK cell subset was found to accumulate [30]. While NK cell
infiltrates of inflamed tissues have been investigated to some
extent, NK cells infiltrating malignant neoplasms have been
poorly characterized, although it is clear that NK cells are
capable of recognizing and killing tumor cells in vitro. In a
recent study, nevertheless, NK cells have been isolated from
non-small-cell lung cancers and analyzed in detail [31]. The
CD56brightCD16− NK cell subset was consistently observed
as being highly enriched in tumor infiltrate and displaying
activation markers, including NKp44, CD69, and HLA-DR.
Remarkably, lung cancers NK cells were mainly capable of
producing cytokines rather than exerting direct cancer cell
killing. A similar pattern of NK cell infiltration, characterized
by abundant CD56brightCD16− NK cells with low cytolytic
activity, has been also reported in renal cell carcinoma
[32, 33]. It might be possible that a chemokine environment
produced by stromal leukocytes might provide anchorage
signals to tumor-infiltrating NK cells. For instance, it has been
suggested that heterodimerization of the chemokine receptor
CCR5, i.e., the receptor of MIP-1β, leads to an adhesive
signal and to the arrest of leukocytes within tissue [34].
Consistent with this notion, only CD56brightCD16− PB NK
cells express CCR5 [20], which might explain their
accumulation in tumor tissues. Thus both CD56dimCD16+
and CD56brightCD16− NK cells might get attracted to
inflamed tissues including tumor sites, but only the latter
subset might be retained there.
NK Cells in Secondary Lymphoid Tissues
Recent reports have shown that a substantial amount of
human NK cells home to secondary lymphoid organs
(SLO). These account for around 5% of mononuclear cells
in uninflamed lymph nodes (LN) and 0.4–1% in inflamed
tonsils and LN [35, 36]. These NK cells constitute a
remarkable pool of innate effector cells, since LN harbor
40% of all lymphocytes, whereas peripheral blood contains
only 2% of all lymphocytes [37, 38]. Therefore, LN NK
cells are under physiological conditions ten times more
abundant than blood NK cells. Remarkably, SLOs might
not only constitute substantial reservoirs of NK cells, but
might even harbor NK cell subsets that are functionally
distinct from their peripheral blood counterparts. For
instance, NKp44+ cells of the mucosal tissue overlaying
tonsils and Peyer’s patches might primarily secrete IL-22
upon activation [39–43]. This peculiar NK cell receptor
carrying cellular subset expresses RORγt and seems to play
a pivotal role in maintaining mucosal homeostasis. How-
ever, IL-22+ NK-like cells are rare cells with an exclusive
localization in the mucosa surrounding the lymphoid
follicles, which might be related to the putative protective
role of IL-22, triggering bactericidal peptide production
against microbial invasion at epithelial and mucosal
surfaces. More in general, and as might be anticipated from
their CCR7 and CD62L expression, SLO NK cells are
mainly composed of the CD56brightCD16− NK cells subset
[36]. Like CD56brightCD16− NK cells of peripheral blood,
secondary lymphoid tissue NK cells are perforin low/
negative and show extremely poor cytolytic activity.
Distinguishing CD56brightCD16− SLO NK cells from their
PB counterparts, however, is their around fivefold elevated
ability to produce IFN-γ in response to activation [44, 45].
In addition, perforin and cytotoxicity can be promptly
upregulated on SLO NK cells by cytokines, and at the same
time, these cells acquire the expression of CD16, as well as
KIRs [36]. Therefore, activation seems to convert second-
ary lymphoid organ NK cells into cytotoxic effector
analogous to blood CD56dimCD16+ NK cells. Several
studies have indeed recently investigated whether PB-
CD56brightCD16− NK cells give rise in vitro and in vivo
to cells akin to CD56dimCD16+ NK cells and whether SLO
can be sites of NK cell maturation [46–48]. These
investigations support the hypothesis that CD56dimCD16+
develop from CD56brightCD16− NK cells, and that this
differentiation can take place both during immune activa-
tion in inflamed peripheral tissues, such as reactive LN, and
in the steady state. Consistent with this hypothesis,
CD56brightCD16− NK cells have longer telomeres than
CD56dimCD16+ NK cells, and could therefore be their
progeny [46, 47]. However, why do NK cells accumulate in
SLOs. One possibility is that the resident population of NK
cells in lymph node might be derived from blood
CD56brightCD16− NK cells, which express CCR7 and
CD62L, two molecules involved in lymphocyte trafficking
to lymphoid tissues [20]. Alternatively, NK cells might also
differentiate directly in SLOs from resident CD34dim
CD45RA+ hematopoietic progenitor cells [49]. In addition,
thymus-derived CD127+ mouse NK cells, which show
characteristics reminiscent of human CD56brightCD16− NK
cells, have been demonstrated to repopulate peripheral
lymphoid organs [50]. Finally, long-lived NK cell popula-
tions might preferentially home to these sites [51].
Therefore, NK cells harbored in secondary lymphoid
tissues could either home there from the blood after their
generation in bone marrow or thymus and/or develop there
as an independent NK-cell lineage.
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NK Cell Activation by DCs
The realization that NK cells are not a homogenous
population of innate lymphocytes, but can mount various
types of innate immune responses that are either dominated
by cytotoxicity or immunoregulatory cytokine secretion,
suggests that the repertoire of NK cell responses might be
differentially triggered by accessory cells. Dendritic cells
(DCs) have been identified as one type of NK cell-
activating cells, and preactivation of NK cells by DCs
was even found to be required for efficient innate immune
responses by these innate lymphocytes against a variety of
pathogenic challenges in the mouse [52–54]. Previously, it
has been realized that NK cells can be efficiently activated
by DCs to elicit antitumor immune responses in mice [55]
and to stimulate IFN-γ production, proliferation, and
enhanced cytotoxicity of NK cells in humans [56–58]. Of
the above-discussed NK cell subsets, the CD56brightCD16−
NK cells, which are enriched in secondary lymphoid tissues
[35, 36], were found to be especially responsive to
activation by DCs [59, 60]. Myeloid DCs preferentially
home to secondary lymphoid tissues upon encounter of
inflammatory stimuli as well as pathogen constituents and
were found to interact with NK cells in perifollicular T cell
zones at these sites [59, 61, 62]. However, not only
myeloid, but also plasmacytoid DCs can activate NK cells,
and these two DC subsets were suggested to stimulate
different NK cell functions via distinct signals [63] (Fig. 1).
Plasmacytoid DCs have been identified as the main type I
IFN-secreting cells upon pathogen encounter [64] and
preferentially augment NK cell cytotoxicity via this
cytokine [63]. Accordingly, protective NK cell cytotoxicity
during infection with the murine cytomegalovirus (MCMV)
was found to be type I IFN dependent [65], and these
cytokines were preferentially produced by plasmacytoid
DCs during this infection [66]. In contrast, myeloid DCs
stimulate IFN-γ production by NK cells efficiently via IL-
12 and IL-18 [45, 59, 63, 67]. In good agreement, IFN-γ
production by NK cells during MCMV infection in vivo
was also primarily IL-12 dependent [68]. IL-12 which is
essential for resistance to MCMV, comes primarily from
myeloid DCs for this innate immune response [66].
Therefore, plasmacytoid and myeloid DCs regulate differ-
ent aspects of NK cell activation with type I IFN of
plasmacytoid DCs increasing NK cell cytotoxicity and IL-
12/IL-18 by myeloid DCs primarily triggering cytokine
production by NK cells. In contrast to the fairly clear roles
of type I IFNs and IL-12 in NK cell activation by DCs,
multiple functions have been assigned to IL-15 in this
interaction. IL-15 presented on DCs via binding to IL-
15Rα has been suggested to stimulate NK cell proliferation
[59], survival [69, 70], type I IFN production [71], and
priming of protective NK cell responses [52]. These
functions, in addition to its crucial role during NK cell
development [72, 73], identify IL-15 as an essential
cytokine for NK cell development and activity, which,
depending on the amount produced by DCs under certain
stimulation conditions, can probably trigger most NK cell
functions. Along these lines, Langerhans cells, a DC subset
originally described in skin, was found to produce more IL-
15 than other myeloid DC subpopulations, thereby support-
ing NK cell survival efficiently [74]. Vice versa, maturation
with polyinosinic-polycytidylic acid (polyI:C), a toll-like
receptor (TLR) 3 agonist, elicited more IL-12 production by
myeloid DCs than other maturation stimuli and the
resulting DCs stimulated proliferation, cytokine secretion,
and enhanced cytotoxicity induction primarily via this
cytokine [45]. These studies suggest that NK cells require
activation by DCs to reach their full functional potential,
and this activation depends on the DC and NK cell subset
involved as well as by which stimulus the DCs have been
matured.
NK Cell Assistance in T-Cell Priming by DCs
NK cells activated in this fashion can fulfill multiple
functions. In addition to the above-discussed mechanisms
for infected and transformed target cell recognition, they can
also shape consecutive adaptive immune responses by causing
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Fig. 1 The cross-talk between dendritic cells (DCs) and NK cells and
their shared receptors. Myeloid DCs (mDCs) primarily activate NK
cells to secrete cytokines like IFN-γ and to proliferate/survive via
production of IL-12/18 and IL-15, respectively. In contrast, NK cell
cytotoxicity is primarily triggered via IFN-α/β, which is mainly
produced by plasmacytoid DCs (pDCs). NK cells, mDCs and pDCs
share pathogen-associated molecular pattern (PAMP) recognition via
TLRs. In addition, both NK cells and mDCs get activated upon
encounter of antibody opsonized targets via CD16/FcγRIIIA and
inhibited via MHC class I recognition by ILT2/LIR1. Contrary to this
synchronized activation or inhibition of mDCs and NK cells, pDCs
get inhibited to secrete type I IFNs by the activating NK cell receptor
NKp44, and vice versa activated to produce IFN-α/β by the inhibitory
NK cell receptor IRp60 (CD300a)
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further DC maturation and influencing the polarization of
primary T-cell responses. In contrast to editing of immune
responses by NK cells that will be discussed in the next
section, these functions support protective immune responses
against intracellular pathogens and tumors that are most
efficiently targeted by Th1 polarized cell-mediated immunity
[61, 75, 76]. NK cell assistance in T-cell priming by DCs is
best achieved by CD56brightCD16− NK cells [44] and in
secondary lymphoid tissues [77], where only low numbers of
cytotoxic NK cells are present [58]. NK cell mediate DC
differentiation and maturation primarily via TNF and IFN-γ
[57, 58, 78]. TNF mainly mediates phenotypical DC
maturation with the up-regulation of costimulatory receptors
[57, 58], while IFN-γ is required for the differentiation of
monocytes into tumor necrosis factor and inducible nitric
oxide synthase producing DCs (TipDCs) during granuloma
formation like after Listeria monocytogenes infection [78].
DC differentiation and maturation allows for the priming of
protective adaptive T-cell responses, therefore offering with
NK cell recognition and alternative mode of maturation apart
from direct recognition of pathogen constituents by DCs
[79–81]. Apart from this role in DC differentiation and
maturation, IFN-γ produced by NK cells contributes to Th1
polarization by probably also directly acting on T cells
during priming [44, 61, 75, 77]. Interestingly, cytokine
secreting CD56brightCD16− NK cells are not only enriched in
secondary lymphoid tissues, where DC-mediated T-cell
priming mainly takes place, but these cells produce also
around fivefold more IFN-γ than their peripheral blood
counterparts and are, therefore, especially suited to assist in
Th1 polarization of primary T-cell responses [44, 45]. These
findings document that NK cells are not only activated by
DCs, but also influence, in turn, adaptive immune responses
that are initiated by these antigen-presenting cells (APCs).
NK Cell Editing of Myeloid APCs
In addition to their support of adaptive immune responses
via DC maturation and T-cell polarization, NK cells have
also the ability to edit myeloid APCs, including macro-
phages, DCs, and microglia, in order to possibly avoid
immunopathology. This preferentially occurs at high numb-
ers of activated NK cells [58]. Immature DCs can be killed
by activated NK cells, and this killing is dependent on the
activating NK cell receptors NKp30, NKp46, and DNAM-1
[56, 82, 83]. In contrast, mature DCs are protected from NK
cell cytotoxicity via their up-regulation of MHC class I
molecules [56]. Especially up-regulation of the nonclassical
HLA class I molecule HLA-E and its mouse counterpart
Qa1b mediates this protection against mainly CD94/
NKG2A carrying NK cells [84, 85]. This cytolytic DC
editing by NK cells has been suggested to reduce graft-
versus-host disease in bone marrow transplantation [86] and
graft rejection in solid organ transplantation [87, 88].
During ameliorated skin graft rejection via this mechanism
NK cells homed to lymph nodes and killed there allogeneic
DCs in a perforin-dependent manner [88]. Therefore,
cytolytic DC editing can limit pathological immune
responses. DCs are, however, not the only myeloid APCs
that can be edited by activated NK cells. Macrophages can
also be targeted by NK cell cytotoxicity. Contrary to DCs,
however, they become more susceptible to NK cell lysis by
activation with TLR agonists [89–91] or infection [92, 93].
Especially high doses of lipopolysaccharide (LPS), a TLR4
agonist, renders macrophages susceptible to NKG2D-
dependent killing by NK cells [89, 90]. Thus, activated,
but not resting macrophages are targeted by activated NK
cells. A third APC population that can be edited by NK cell
cytotoxicity are microglial cells, resident APCs of the
central nervous system (CNS) [94, 95]. Similar to DCs,
resting microglia is sensitive to NK cell cytotoxicity,
whereas activation by TLR4 ligation with LPS protects
these cells from NK cell lysis by up-regulation of MHC
class I molecules [95]. Resting microglia recognition is
mediated by the activating NK cell receptors NKG2D and
NKp46 [95]. These studies suggest that resting DCs,
activated macrophages, and resting microglial cells can be
targeted by activated NK cells, and cytotoxic editing of
these myeloid APCs attenuates immunopathology, for
example, in transplantation settings.
NK Cell and DC Recognition of Similar Stimuli
Consistent with their concomitant role during the early phase
of immune responses, NK cells and DCs are often able to
sense similar stimuli in parallel. It has been reported that
stimuli acting on TLRs not only activate immature dendritic
cells but also render NK cells more prone to receive triggering
signals from pathogen-associated molecules, thus exerting a
regulatory control on the early steps of innate immune
responses against infectious agents [96]. While TLR engage-
ment results similarly for both DCs and NK cells in
activation, recognition of self-MHC class I molecules, the
main mechanism to restrain NK cell activity, can also inhibit
other leukocyte populations. For intance, myelomonocytic
cells, including myeloid DCs (mDCs), express ILT2, an
inhibitory receptor expressed on subsets of NK cells. This
receptor binds MHC class I molecules and delivers a
negative signal that inhibits killing by NK cells. In addition,
ILT2 engagement also dampens Ca2+ mobilization in mDCs
triggered through human histocompatibility leukocyte anti-
gens (HLA)-DR [97, 98]. Most recently, plasmacytoid DCs
(pDCs), also known as natural interferon-producing cells,
have been shown to express receptors that are typically
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employed for NK cell recognition. One of these receptor,
NKp44, is present on a subset of pDCs in SLOs and is
inducible on PB pDCs after in vitro culture with interleukin
3. Crosslinking of NKp44 on NK cells is associated with
triggering of NK cell-mediated cytotoxicity. Paradoxically,
crosslinking of NKp44 on pDCs does not trigger their
functions but significantly inhibits interferon (IFN)-α pro-
duction in response to cytosine-phosphate-guanosine (CpG)
oligonucleotides [99]. Since IFN-α is a potent inducer of NK
cell cytotoxicity, the recognition of the same ligand by
receptors mediating divergent outcomes might appear con-
tradictory. Nevertheless, pDCs in tonsils are in close contact
with CD8+ T cells that are able to produce IL-3 [99]. In this
context, expression of NKp44 on pDCs and the inhibition of
IFN-α by putative NKp44 ligands would occur when an
adaptive response is already taking place, and further, NK
cell activation might no longer be required. In addition,
IRp60 (CD300a) is another inhibitory receptor expressed by
NK cells, as well as by many other leukocytes and also
displayed an unpredicted role when cross-linked on pDCs.
IRp60 triggering reduced, as expected, TNF-α but increased
IFN-α secretion by pDCs [100]. Because exogenous TNF-α,
a cytokine abundantly released by activated NK cells,
inhibits IFN-α secretion by pDCs [101], these new findings
support the notion that there is a balance between IFN-α and
TNF-α levels produced by pDC and NK cells. However,
pDCs express also CD300c, which shares with CD300a 80%
amino acid sequence similarity in their Ig domains. CD300a
contains three immunoreceptor tyrosine-based inhibitory
motifs (ITIMs), of which at least one is functional in NK
cells [102]. CD300c has a short intracellular domain with
charged amino acid in the transmembrane domain, which
may be associated with other signaling molecules. Thus,
although these CD300 receptors may share a common
ligand, they almost certainly have different intracellular
pDC signaling capabilities. Defining the natural ligands of
NKp44 and CD300a/c will shed further light on the complex
cross-talk between DCs and NK cells upon recognition of
similar stimuli early during immune responses, setting
eventually the stage for establishing adaptive immune
responses that confer long-term protection.
Conclusions
The cross-talk between NK cells and DCs suggests a
critical role for NK cells in the initiation and regulation of
immune responses. The considerable knowledge on the
molecular basis of these cellular interactions offers oppor-
tunities for clinical intervention exploiting DC/NK cell
cooperation. Indeed, NK cell activation by DCs is partic-
ularly efficient since DC promote both effector functions
and survival or proliferation of NK cells. In addition, recent
publications in the field of semi-allogeneic bone marrow
transplantation have highlighted a beneficial role of NK
cells in mediated graft-versus-leukemia effects, and NK
cell-based immunotherapies are, therefore, currently being
reconsidered [103]. Along these lines, the ability of NK
cells to kill tumor cells may facilitate the generation of
tumor-derived antigenic material that can be efficiently
presented by DCs, further accelerating the induction of
tumor-specific immunity [81].
In addition to their traditional role as major innate
cytotoxic cells, NK cells have now been shown to regulate
immune responses. On one hand, they provide immuno-
regulatory “helper” functions, being able to activate DCs
for pro-inflammatory cytokine production and for efficient
Th1 and cytotoxic T lymphocyte (CTL) stimulation. As a
matter of fact, DCs activated by NK cells are better
inducers of antitumor CTL response, at least in vitro, when
compared with the standard mature DCs currently
employed in DC-based clinical trials [104]. On the other
hand, they can edit myeloid APC populations to attenuate
and direct immune responses [105]
All these considerations provide a strong rationale for a
combined targeting of NK cells and DCs in novel immuno-
therapeutic strategies, harnessing this cellular cross-talk in
the treatment of patients with cancer and chronic infections
that are resistant to conventional therapies.
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